Daraxonrasib nearly doubles survival in advanced pancreatic cancer by targeting previously 'undruggable' mechanism
By
Christopher Lieu
An everything bagel for the brain. Substantive, layered, well-seasoned.
Summary
A new drug called daraxonrasib has shown promise in nearly doubling survival rates for patients with advanced pancreatic cancer. Pancreatic cancer has historically been extremely deadly, with about 97% of metastatic patients dying within five years, due to lack of effective screening and late symptom onset. The drug targets a mechanism previously considered 'undruggable,' offering new hope for treating this aggressive disease. An oncologist explains how the breakthrough works and what it means for patients.
Key quotes
· 4 pulledFor a long time, the likelihood of surviving pancreatic cancer has been extremely low.
For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.
Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages.
By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs.
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·3d ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo ago
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·9mo ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Ask HN: What is the latest on treatment of Metastatic Breast Cancer?
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·8mo ago